Flumazenil Injection
Last Updated: January 31, 2017
Status: Current
Products Affected - Description
All presentations are currently available
Reason for the Shortage
- Fresenius Kabi had flumazenil on shortage due to short-term manufacturing delays.
- Mylan Institutional could not provide a reason for the shortage.
- Sandoz discontinued flumazenil injection in 2015.
- West-Ward stated the reason for the shortage is increased demand.
Available Products
Flumazenil injection, Fresenius Kabi
0.1 mg/mL, 10 mL vial, 10 count (NDC 67457-0444-10)
0.1 mg/mL, 5 mL vial, 10 count (NDC 00143-9784-10)
Estimated Resupply Dates
All marketed presentations are available.
Related Shortages
- Acetaminophen and Codeine Phosphate 300 mg/30 mg Tablets — Resolved
- Cefepime Injection — Current
- Dexmethylphenidate Hydrochloride — Resolved
- Levorphanol Tablets — Resolved
- Methylphenidate Hydrochloride Chewable Tablets — Current
- Methylphenidate Hydrochloride Extended Release Oral Presentations — Resolved
- Methylphenidate Hydrochloride Immediate Release Tablets — Resolved
- Methylphenidate Transdermal — No Commercially Available Preparations
- Pramipexole Dihydrochloride Tablets — Resolved
- Reserpine Oral Tablets — No Longer Available — No Commercially Available Preparations
- Rotigotine Transdermal Systems (Neupro) — Resolved
Updated
January 31, 2017; December 1, November 9, September 27, July 26, 15 and 7, May 25, January 12, 2016; December 30 and 15, November 30 and 17, October 20, 12 and 2, September 18, August 12, July 28, June 15, 2015, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.